Generic Product News

Published Online: Thursday, September 13, 2012
Follow Pharmacy_Times:

Methotrexate Injection, USP

Marketed by: Teva Pharmaceuticals
Compare to: Folex (discontinued) (Pharmacia Corporation, now part of Pfizer Inc)
Indication: Teva Pharmaceuticals announces the introduction of its generic methotrexate injection for the treatment of certain cancers, including acute lymphoblastic leukemia, severe psoriasis that has not responded to other forms of therapy, and adult rheumatoid arthritis. It is non-pyrogenic and may be administered by intramuscular, intravenous, or intra-arterial routes. The injection is free of both latex and plastic. The injection can cause fetal death or birth defects when administered to pregnant women, and pregnancy should be avoided if either partner is on the medication.
Dosage Form: 25 mg/mL single-dose glass vials and in 50 mg, 100 mg, 250 mg, and 1 g doses
For More Information:

Oxycodone HCl Capsules
Marketed by: Midlothian Laboratories (Montgomery, AL)
Compare to: Oxycodone HCl 5 mg (Lehigh Valley Technologies Inc.)
Indication: Midlothian Laboratories has begun distributing oxycodone in capsule form, an AB-rated generic equivalent of Lehigh Valley Technologies' Oxycodone HCl 5 mg. It is indicated for the management of moderate to severe acute and chronic pain and is available in a single strength. Each gelatin capsule contains 5 mg of the drug, and should be taken every 4 to 6 hours as needed.
Dosage Form: Capsules: 5 mg
For More Information:

Calcipotriene Cream
Marketed by: Sandoz Inc (Princeton, NJ)
Compare to: Dovonex (LEO Pharma Inc)
Indication: Sandoz has introduced calcipotriene cream, the first generic version of LEO Pharma Inc’s Dovonex Cream. The cream is indicated for the treatment of plaque psoriasis and contains a synthetic vitamin D3 derivative that is absorbed systemically. It is applied to psoriasis plaques on the body twice daily but should not be used on the face.
Dosage Form: Topical cream: 0.005% in 60- and 120-g tubes
For More Information:

Levalbuterol HCl Inhalation Solution
Marketed by: Prasco Laboratories (Mason, OH)
Compare to: Xopenex (Sunovion Pharmaceuticals Inc)
Indication: Prasco Laboratories and Sunovion Pharmaceuticals Inc will begin distributing levalbuterol HCL, an authorized generic version of Sunovion’s Xopenex inhalation solution. It is indicated for the prevention or relief of bronchospasm caused by asthma and chronic obstructive pulmonary disease. The medication can be used by adults, adolescents, and children 4 years and older.
Dosage Form: Metered-dose inhaler: 1.25 mg/ 3 mL, 0.63 mg/3 mL, and 0.31 mg/3 mL strengths
For More Information:

Related Articles
The FDA today approved sirolimus, the first drug to treat lymphangioleiomyomatosis, a rare lung disease.
Amgen has terminated its co-development and commercialization of brodalumab with AstraZeneca after observing suicidal ideation and behavior in clinical trial participants.
The FDA today approved a new treatment for chronic obstructive pulmonary disease: tiotropium bromide and olodaterol inhalation spray.
Clinical guidelines and government agencies are increasingly encouraging clinicians to consider patients’ treatment preferences when chronic disease is present.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times